Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 187-194, May 2009

Association between the FABP2 Ala54Thr, PPARα Leu162/Val, and PPARα intron7 polymorphisms and blood lipids ApoB and ApoCIII in hypertriglyceridemic subjects in Tehran

  • Hamideh Pishva, PhD

      Affiliations

    • Department of Nutrition and Biochemistry, School of Public Health and Institute of Public Research, Tehran University of Medical Sciences, Tehran, Iran
  • ,
  • Soltan Ali Mahboob, PhD

      Affiliations

    • Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
    • Corresponding Author InformationCorresponding author.
  • ,
  • Parvin Mehdipour, PhD

      Affiliations

    • Department of Medical Genetic, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • ,
  • Mohammad Reza Eshraghian, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Research, Tehran University of Medical Sciences, Tehran, Iran
  • ,
  • Javad Mohammadi-Asl, MS

      Affiliations

    • Department of Genetics, School of Medicine, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
  • ,
  • Saeed Hosseini, MD, PhD

      Affiliations

    • Endocrinology Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
  • ,
  • Mazaher Rahmany, BS

      Affiliations

    • Endocrinology Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran

Received 4 September 2008; accepted 13 April 2009. published online 20 April 2009.

Background

The alanine to threonine substitution at codon 54 in the FABP2 gene and PPARα Val162 allele have been associated with hypertriglyceridemia.

Objective

We sought to determine the prevalence of the Ala54Thr polymorphism of fatty acid binding protein (FABP) 2 gene and the Leu162/Val in exon 5 and G/C in intron7 polymorphism of peroxisome proliferator-activated receptor alpha (PPARα) gene in hypertriglyceridemic patients and their associations with blood lipid concentrations.

Methods

A total of 170 hypertriglyceridemic subjects were enrolled and genotyped for Ala54Thr, Leu162Val, and intron 7 polymorphism by the use of a polymerase chain reaction-restriction fragment length polymorphism method. Fasting blood triglyceride, total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein (Apo)B, and ApoCIII also were determined.

Results

We found frequency of 81.2% for the Thr54 polymorphism among hypertriglyceridemic subjects. Positive associations were observed between this polymorphism and greater blood triglyceride, very low-density lipoprotein, and ApoCIII levels and lower blood high-density lipoprotein cholesterol concentration both in men and women. However, no association was found between the Thr54 polymorphism and TC, low-density lipoprotein cholesterol, ApoB, and body mass index. Frequency of the Leu162Val polymorphism was 21.8%. The Leu162Val polymorphism was not associated with lipid and lipoprotein concentrations in hypertriglyceridemic subjects (both in men and women). The frequency of intron7 polymorphism was 55.3% in subjects studied and, except for body mass index and TC, no association was found between the intron7 allele and blood lipids ApoB, and ApoCIII.

Conclusion

Frequency of the Thr54 polymorphism is high in hypertriglyceridemic subjects, and the presence of this allele may increase some blood lipid and lipoprotein concentrations. In addition, the frequency of intron7 polymorphism may be greater than Leu162Val in hypertriglyceridemic patients.

Keywords: FABP2, PPARα, Intron7, Polymorphism, Hypertriglyceridemia, Blood lipids, ApoB, ApoCIII, HDL-C, VLDL

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1933-2874(09)00148-2

doi:10.1016/j.jacl.2009.04.001

Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 187-194, May 2009